Leucid
London, GB · 3 known investors
Leucid Bio develops CAR-T cell therapies based on a proprietary Lateral CAR platform that redesigns the CAR structure to mimic the lateral signalling arrangement of natural immune receptors. The technology, derived from 20 years of research led by Dr John Maher at King's College London, aims to increase T-cell potency and durability while reducing toxicity.
Founders & leadership
JM
John MaherFounder
Investors · 3
Competitors · 2
by search overlapBioworld6 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Kite Pharma5 shared keywordsKite Pharma develops CAR T-cell therapies for cancer patients, engineering the immune system's cells to target and attack cancer. Each therapy is individualized per patient through a multi-step manufacturing process.
Companies competing with Leucid for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Leucid do?
- Leucid Bio develops CAR-T cell therapies based on a proprietary Lateral CAR platform that redesigns the CAR structure to mimic the lateral signalling arrangement of natural immune receptors. The technology, derived from 20 years of research led by Dr John Maher at King's College London, aims to increase T-cell potency and durability while reducing toxicity.
- Who founded Leucid?
- Leucid was founded by John Maher.
- Who are Leucid's investors?
- Leucid's investors include Sofinnova Partners, Vulpes Investment Management, Epidarex Capital.
- Where is Leucid headquartered?
- Leucid is headquartered in London, GB.